机构：[1]Breast Center, The Fourth Hospital of Hebei Medical University, No.12 Jiankang Road, Shijiazhuang 050011,Hebei, China.河北医科大学第四医院[2]Department of Haematology, The Fourth Hospital of Hebei Medical University, No.12 JiankangRoad, Shijiazhuang 050011, Hebei, China.临床科室血液内科河北医科大学第四医院[3]The State Key Laboratory of Translational Medicine and InnovativeDrug Development, Jiangsu Simcere Diagnostics Co., Ltd., No.699‑18 Xuanwu Avenue, Nanjing 210042, Jiangsu,China.[4]Department of Breast Surgery, Xingtai People’s Hospital, No.16 Hongxing Street, Xingtai 054031, Hebei,China.[5]Department of Pathology, The Fourth Hospital of Hebei Medical University, No.12 Jiankang Road,Shijiazhuang 050011, Hebei, China医技科室病理科河北医科大学第四医院
RecurIndex, a multigene profiling assay, can predict the risk of local recurrence and distant metastasis in female breast cancer (FBC), but its role in male breast cancer (MBC) remains unclear. In this study, the clinicopathological data of 43 consecutive MBC patients undergoing surgeries between 2009 and 2018 were retrospectively analysed. Their paraffin-embedded tissue sections were examined by RecurIndex test which comprised 2 models: recurrence index for local recurrence (RI-LR) and recurrence index for distant recurrence (RI-DR). Of 43 patients, there were 26 low-risk and 17 high-risk patients assessed by RI-LR, while 17 low-risk and 26 high-risk patients by RI-DR. For RI-LR, tumor N stage showed statistically significant (P < 0.001) between low- and high-risk patients; for RI-DR, differences were pronounced in tumor grade (P = 0.033), T stage (P = 0.043) and N stage (P = 0.003). In terms of clinical outcomes, the overall survival (OS) of low- and high-risk patients stratified by RI-LR showed no statistically significant differences (P = 0.460), while high-risk patients identified by RI-DR had a significantly worse distant recurrence-free survival (DRFS) (P = 0.035), progression-free survival (PFS) (P = 0.019) and OS (P = 0.044) than low-risk patients. Overall, RI-DR can effectively predict the DRFS, PFS and OS of MBC patients and identify those at low risk of recurrence, which may serve as a potential prognostic tool for MBC.
基金：
Institutional Review Board
of The Fourth Hospital of Hebei Medical University (Approval No.: 20211372).
第一作者机构：[1]Breast Center, The Fourth Hospital of Hebei Medical University, No.12 Jiankang Road, Shijiazhuang 050011,Hebei, China.
共同第一作者：
通讯作者：
通讯机构：[1]Breast Center, The Fourth Hospital of Hebei Medical University, No.12 Jiankang Road, Shijiazhuang 050011,Hebei, China.
推荐引用方式(GB/T 7714)：
Zhang Shuo,Liu Beichen,Zhou Mengli,et al.The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients.[J].SCIENTIFIC REPORTS.2021,11(1):doi:10.1038/s41598-021-87267-y.
APA：
Zhang Shuo,Liu Beichen,Zhou Mengli,Wang Jintian,Liu Jinzhao...&Liu Yunjiang.(2021).The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients..SCIENTIFIC REPORTS,11,(1)
MLA：
Zhang Shuo,et al."The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients.".SCIENTIFIC REPORTS 11..1(2021)
